1 |
罗华.静脉注射胺碘酮治疗快速性心律失常的临床观察探究[J].心血管病防治知识,2016,7:62-64.
|
2 |
中国生物医学工程学会心脏起搏与心电生理分会,中华医学会心血管病学分会,中华心血管病杂志编辑委员会,等.胺碘酮抗心律失常治疗应用指南[J].中华心血管病杂志,2004,32(12):1065-1071.
|
3 |
龚金龙.胺碘酮治疗扩张型心肌病心力衰竭并发室性心动过速的疗效和安全性[J].临床合理用药,2009,2(23):44-45.
|
4 |
龙明智,黄元铸.快速心律失常的诊断及其鉴别要点[J].中国医师进修杂志,1993,5:37-38.
|
5 |
Yusuf S. The global problem of cardiovascular disease[J]. Int J Clin Pract Suppl, 1998, 94: 3-6.
|
6 |
Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines(Writing Committ ee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death)developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Europace, 2006, 8(9): 746-837.
|
7 |
方萍,李幸祥,刘光辉,等.上海市2013至2015年可除颤室性心律失常院前急救分析[J].临床与病理杂志,2016,36(3):270-274.
|
8 |
冯庚,彭晓霞.院前静注普罗帕酮治疗快速心律失常的安全性研究[J].中华急诊医学杂志,2013,22(4):441-445.
|
9 |
ECC Committee, Subcommittees and Task Forces of the American Heart Association.2005 American Heart Association Guidelines for Cardiopulnmnary Resuscitation and Emergency Cardiovascular Care[J]. Circulation, 2005, 112(24 Suppl): IVl-203.
|
10 |
Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell[J]. Cire Res, 2009, 105(12): 1164-1176.
|
11 |
杜海霞.美托洛尔联合胺碘酮治疗慢性心力衰竭并室性心律失常疗效分析[J].医药论坛杂志,2011, 32(24):126-127.
|
12 |
潘竞贤,程淑霞,白冰.85例老年危重患者心律失常静注胺碘酮临床疗效分析[J].武警后勤学院学报(医学版),2014,23(5):425-426.
|
13 |
黄辉权.急诊应用胺碘酮治疗快速性心律失常的疗效观察[J].中国实用医药,2011,6(10):146-147.
|
14 |
Wang CZ, Li XL, Wang QF, et al. Selective fraction of Scutellaria baicalensis and its chemopreventive effects on MCF-7 human breast cancer cells[J]. Phytomedicine, 2010, 17(1): 63-68.
|
15 |
杨旺明,廖云,叶泽兵,等.院前急救应用可达龙治疗快速性心律失常疗效观察[J].岭南急诊医学杂志,2011,16(3):222-223.
|
16 |
陆元汉.院前静脉应用可达龙治疗快速性心律失常的疗效观察[J].基层医学论坛,2008,12(20):588-589.
|
17 |
Echt DS, Lieboson PR, Mitchell LB, et al.MortAlity and morbidity in patients receiving encainide, flecainide, or placebo, the Cardiac Arrhythmia SuppressionTrial[J]. N Engl JMed, 1991, 324(12): 781 -788.
|
18 |
Cardiac Arrhythmia Suppression Trial II Investigators.Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.The cardiac arrhythmia suppression trial II investigators[J]. N Engl J Med, 1992, 327(4): 227-223.
|
19 |
Doval HC, Nul DR, Grancelli HO, et al.Randomised trial of low-dose amiodarone in severe congestive heart failure.Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)[J]. Lancet, 1994, 344(8921): 493 -498.
|